A prospective, randomized controlled study on the treatment of stage c and stage d prostatic cancer with estracyt in combination with other chemotherapeutic agents

Japanese Journal of Clinical Oncology

Volumn 18, Issue 4, 1988, Pages 343-355

  Akaza, Hideyuki ^a   Isurugi, Koichiro ^b   Oishi, Yukihiko ^c   Kitajima, Kiyoaki ^d   Sawamura, Yoshikatsu ^e   Baba, Shiro ^f   Yoshida, Kazuhiro ^g   Otani, Mikinobu ^h   Harada, Masaaki ⁱ   Gunji, Atsuaki ^a   Aso, Yoshio ^a   Niijima, Tadao ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b TOKYO TEISHIN HOSPITAL   (Japan)

^c JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d NIHON UNIVERSITY   (Japan)

^e TOHO UNIVERSITY   (Japan)

^f KEIO UNIVERSITY   (Japan)

^g NIPPON MEDICAL SCHOOL   (Japan)

^h UNIVERSITY OF TSUKUBA   (Japan)

ⁱ KANAGAWA CANCER CENTER   (Japan)

Author keywords

Chemotherapy; Estracyt; Peplomycin; Prostatic cancer; Response criteria

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORMETHINE DERIVATIVE; DIETHYLSTILBESTROL; DOXORUBICIN; DRUG DERIVATIVE; ESTRAMUSTINE; FLUOROURACIL; FOSFESTROL; PEPLEOMYCIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL TRIAL; HUMAN; MALE; MORTALITY; PATHOLOGY; PROSPECTIVE STUDY; PROSTATE TUMOR; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; DIETHYLSTILBESTROL; DOXORUBICIN; ESTRAMUSTINE; FLUOROURACIL; HUMAN; MALE; MIDDLE AGE; NEOPLASM STAGING; NITROGEN MUSTARD COMPOUNDS; PEPLOMYCIN; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RANDOM ALLOCATION;

EID: 0024226148     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Beckley, S., Wajsman, L. Z., Slack, N. H. and Murphy, C. P. Chemotherapy in metastatic, hormone refractory prostatic cancer using chlorambucil in combination with prednisolone versus conjugate, prednimustine (LEO 1031) Urology 5, 446-448 (1981).
2. Murphy, G. P., Beckley, S., Brady, F., Chu, T. M., de Kernion, J. B., Gaeta, J. F., Gibbons, R. P., Loening, S. A., McKiel, C. F., Mcleod, D. G., Pontes, J. E., Prout, G. R., Scardino, P. T., Schlegel, J. U., Schmidt, J.D., Scott, W.W., Slock, N. H. and Soloway, M. S. Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer 51, 1264-1283 (1983).
3. Smith, P. H., Suciu, S., Robinson, M. R. G., Richards, B., Bastable, J. R. G., Glashan, R. W., Bouffiaux, C., Lardennois, B., Williams, R. E., De Pauw, M. and Sylvester, R. A comparison of the effect of diethylstilbestrol with low dose estramustine phosphate in the treatment of advanced prostatic cancer: Final analysis of phase III trial of the European Organization for Research on Treatment of Cancer. J. Urol. 136, 619-625 (1986).
4. Akaza, H., Usami, M., Kotake, T., Matsumura, Y., Moriyama, N., Imai, K., Fuse, H., Isaka, S., Yamanaka, H., Matsumoto, K. and Shimazaki, Z. Response criteria for prostatic cancer treated with chemotherapy or anti-androgenic therapy. Acta Urol. Japonica 33, 894-904 (1987).
5. Citrin, D. L. and Hogan, T. F. A phase II evaluation of adriamycin and cisplatinum in hormone resistant prostatic cancer. Cancer 50, 201-206 (1982).
6. Muss, H. B, Howard, V., Richards, F., White, D. R., Jackson, D. V., Cooper, M. R., Stuart, J. J., Resnick, M. I., Brodkin, R. and Spurr, C. L. Cyclophosphamide versus cyclophosphamide, methotrexate and 5-fluorouracil in advanced prostatic cancer. Cancer 47, 1949-1953 (1981).
7. Yagoda, A. Cytotoxic agents in prostate cancer: An enigma. Semin. Urol. 4, 311-322 (1983).
8. Küss, R., Khoury, S., Richard, F., Fourcade, F., Frantz, P. and Capelle, J. P. Estramustine phosphate in the treatment of advanced prostatic cancer. Cancer 52, 29-33 (1980).
9. Slack, N. H., Wajsman, Z., Mittelman, A., Bruno, S. and Murphy, G. P. Relationship of prior hormonal therapy to subsequent estramustine phosphate treatment in advanced prostatic cancer. Urology 14, 549-554 (1979).
10. Soloway, M.S., Beckley, S., Brady, M. F., Chu, T. M., de Kernion, J. B., Dhabuwala, C, Gaeta, J. F., Gibbons, R. P., Loening, S. A., McKiel, C. F., McLeod, D. G., Pontes, J. E., Prout, G. R., Scardino, P. T., Schlegel, J.U., Schmidt, J.D., Scott, W. W., Slack, N. H. and Murphy, G. P. A comparison of estramustine phosphate versus cis-platinum alone versus estramustine plus cisplatinum in patients with advanced hormone refractory prostate cancer who had had extensive irradiation to the pelvis or lumbosacral area. J. Urol. 129, 56-61 (1983).
11. Veronesi, A, Zattoni, F., Frustaci, S., Galligioni, E., Tirelli, U., Trovo, G., Tumolo, S., Merlo, A., Artuso, G., Cosciani-Cunico, S. and Grigoletto, E. Estramustine phosphate (Estracyt) treatment of T3-T4 prostatic carcinoma. Prostate 3, 159-164 (1982).
12. Niijima, T., Akaza, H., Koiso, K., Isurugi, K. and Ichikawa, T. Clinical studies on peplomycin: Trial on prostatic cancer. 13th Int. Natl. Congress Chemother. (Separatum) (1983).
13. Paulson, D. F., Berry, W. R., Cox, E. B., Walker, A. and Laszlo, J. Treatment of metastatic endocrine-unresponsive carcinoma of the prostate gland with multiagent chemotherapy: Indicators of response to therapy. J. Natl. Cancer Inst. 63, 615-622 (1979).